Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Capital Expenditures: 2009-2025

Historic Capital Expenditures for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $5.4 million.

  • BIO-TECHNE's Capital Expenditures fell 41.53% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year decrease of 53.48%. This contributed to the annual value of $31.0 million for FY2025, which is 50.69% down from last year.
  • As of Q3 2025, BIO-TECHNE's Capital Expenditures stood at $5.4 million, which was up 9.67% from $4.9 million recorded in Q2 2025.
  • BIO-TECHNE's 5-year Capital Expenditures high stood at $18.0 million for Q2 2024, and its period low was $4.9 million during Q2 2025.
  • Over the past 3 years, BIO-TECHNE's median Capital Expenditures value was $10.8 million (recorded in 2023), while the average stood at $11.1 million.
  • Per our database at Business Quant, BIO-TECHNE's Capital Expenditures surged by 143.31% in 2023 and then slumped by 72.80% in 2025.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Capital Expenditures stood at $10.2 million in 2021, then tumbled by 39.92% to $6.1 million in 2022, then spiked by 143.31% to $14.9 million in 2023, then crashed by 54.11% to $6.8 million in 2024, then slumped by 41.53% to $5.4 million in 2025.
  • Its Capital Expenditures was $5.4 million in Q3 2025, compared to $4.9 million in Q2 2025 and $10.1 million in Q1 2025.